2020
Evaluation of Photon and Proton Radiotherapy Plan Quality With the Knowledge-Based Approach in NRG BN001 Clinical Trial
Wang D, Gondi V, Tsien C, Chenevert T, Gilbert M, Omuro A, McDonough J, Aldape K, Cao Y, Srinivasan A, Rogers L, Grimm S, Huang J, Machtay M, Martinez N, Bahary J, Nedzi L, Mehta M, Xiao Y. Evaluation of Photon and Proton Radiotherapy Plan Quality With the Knowledge-Based Approach in NRG BN001 Clinical Trial. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e344-e345. DOI: 10.1016/j.ijrobp.2020.07.822.Peer-Reviewed Original Research
2015
QOL-07DESCRIPTION OF CLINICAL AND PATIENT REPORTED OUTCOMES ASSESSMENTS FROM A PHASE 3, MULTICENTER, RANDOMIZED TRIAL EVALUATING NIVOLUMAB MONOTHERAPY VERSUS BEVACIZUMAB IN RECURRENT GLIOBLASTOMA: CHECKMATE-143
Nayak L, Brandes A, Omuro A, Rieger J, Wick A, Phuphanich S, Sumrall A, Sahebjam S, Ahluwalia M, de Souza P, Sepulveda J, Maio M, Grauer O, Vlahovic G, Baehring J, Dastani H, Latek R, Coric V, Reardon D. QOL-07DESCRIPTION OF CLINICAL AND PATIENT REPORTED OUTCOMES ASSESSMENTS FROM A PHASE 3, MULTICENTER, RANDOMIZED TRIAL EVALUATING NIVOLUMAB MONOTHERAPY VERSUS BEVACIZUMAB IN RECURRENT GLIOBLASTOMA: CHECKMATE-143. Neuro-Oncology 2015, 17: v189-v189. PMCID: PMC4639164, DOI: 10.1093/neuonc/nov230.07.Peer-Reviewed Original ResearchPatterns of response and relapse of primary central nervous system lymphomas (PCNSL) following first line of high-dose methotrexate-based chemotherapy (hdMTX): Analysis of a prospective ANOCEF randomized phase II trial.
Tabouret E, Houillier C, Martin-Duverneuil N, Blonski M, Soussain C, Ghesquieres H, Houot R, Delwail V, Soubeyran P, Gressin R, Gyan E, Chinot O, Taillandier L, Tanguy M, Omuro A, Hoang-Xuan K. Patterns of response and relapse of primary central nervous system lymphomas (PCNSL) following first line of high-dose methotrexate-based chemotherapy (hdMTX): Analysis of a prospective ANOCEF randomized phase II trial. Journal Of Clinical Oncology 2015, 33: 2035-2035. DOI: 10.1200/jco.2015.33.15_suppl.2035.Peer-Reviewed Original Research
2014
Phase IB trial of carboxyamidotriazole orotate (CTO) and temozolomide for recurrent malignant glioma (MG): A novel mechanism for modulation of multiple oncogenic pathways.
Omuro A, Kaley T, Pentsova E, DeAngelis L, Urba W, Taylor M, Anderson B, Gorman G, McLean S, Karmali R. Phase IB trial of carboxyamidotriazole orotate (CTO) and temozolomide for recurrent malignant glioma (MG): A novel mechanism for modulation of multiple oncogenic pathways. Journal Of Clinical Oncology 2014, 32: 2071-2071. DOI: 10.1200/jco.2014.32.15_suppl.2071.Peer-Reviewed Original Research
2011
Multicenter phase II trial of temozolomide (TMZ) and rituximab (RIT) for recurrent primary CNS lymphoma (PCNSL): North American Brain Tumor Consortium (NABTC) study 05-01.
Nayak L, Abrey L, Drappatz J, Gilbert M, Reardon D, Lamborn K, Wen P, Prados M, DeAngelis L, Omuro A. Multicenter phase II trial of temozolomide (TMZ) and rituximab (RIT) for recurrent primary CNS lymphoma (PCNSL): North American Brain Tumor Consortium (NABTC) study 05-01. Journal Of Clinical Oncology 2011, 29: 2039-2039. DOI: 10.1200/jco.2011.29.15_suppl.2039.Peer-Reviewed Original ResearchTargeted Therapy for Malignant Gliomas
Dankwah-Quansah M, Omuro A. Targeted Therapy for Malignant Gliomas. Tumors Of The Central Nervous System 2011, 299-307. DOI: 10.1007/978-94-007-0344-5_31.Peer-Reviewed Original ResearchMalignant gliomasAggressive primary brain tumorFatal disease outcomeSingle-agent trialsSingle-agent treatmentPrimary brain tumorsAkt/mTORDevelopment of combinationsAgent trialsDismal prognosisPatient selectionStandard treatmentTargeted therapyDisease outcomeAnaplastic astrocytomaAnaplastic oligodendrogliomaBrain tumorsTherapy trialsNew treatmentsPathway inhibitionGliomasAgent treatmentTrialsRas/MAPKPromising activity
2010
Phase II trial of continuous low-dose temozolomide (TMZ) for recurrent malignant glioma (MG) with and without prior exposure to bevacizumab (BEV).
Khasraw M, Abrey L, Lassman A, Hormigo A, Nolan C, Gavrilovic I, Mellinghoff I, Reiner A, DeAngelis L, Omuro A. Phase II trial of continuous low-dose temozolomide (TMZ) for recurrent malignant glioma (MG) with and without prior exposure to bevacizumab (BEV). Journal Of Clinical Oncology 2010, 28: 2065-2065. DOI: 10.1200/jco.2010.28.15_suppl.2065.Peer-Reviewed Original ResearchMulticenter randomized phase II trial of methotrexate (MTX) and temozolomide (TMZ) versus MTX, procarbazine (PCB), vincristine (VINC), and cytarabine (Ara-C) for primary CNS lymphoma (PCNSL) in elderly patients.
Omuro A, Taillandier L, Chinot O, Ghesquieres H, Soussain C, Delwail V, Choquet S, Tanguy M, Lamy T, Hoang-Xuan K. Multicenter randomized phase II trial of methotrexate (MTX) and temozolomide (TMZ) versus MTX, procarbazine (PCB), vincristine (VINC), and cytarabine (Ara-C) for primary CNS lymphoma (PCNSL) in elderly patients. Journal Of Clinical Oncology 2010, 28: tps144-tps144. DOI: 10.1200/jco.2010.28.15_suppl.tps144.Peer-Reviewed Original Research
2008
Brain tumors and dementia
Omuro AM, Delattre J. Brain tumors and dementia. Handbook Of Clinical Neurology 2008, 89: 877-886. PMID: 18631803, DOI: 10.1016/s0072-9752(07)01277-8.Peer-Reviewed Original ResearchConceptsCognitive dysfunctionBrain tumorsAdult brain tumor patientsMinor cognitive dysfunctionBrain tumor patientsQuality of lifeDiffuse cognitive dysfunctionSuch patientsTumor patientsPatient's lifeCognitive impairmentPatientsCognitive endpointsCognitive functionDysfunctionCommon typeDementiaTumorsDeleterious impactMildDiagnosisImpairmentTrialsEndpoint
2007
Editorial: what is new in the treatment of gliomas?
Omuro AM, Delattre JY. Editorial: what is new in the treatment of gliomas? Current Opinion In Neurology 2007, 20: 704-707. PMID: 17992093, DOI: 10.1097/wco.0b013e3282f1beef.Peer-Reviewed Original ResearchConceptsTreatment of gliomaTherapeutic decisionsEvidence-based therapeutic decisionsBevacizumab-based combinationsRecurrent malignant gliomaRole of chemotherapyPhase II trialStandard of carePhase III evidenceHigh response ratePhase II resultsSingle positive resultTemozolomide concomitantTemozolomide schedulesII trialSurvival benefitRandomized trialsGrade IIIMalignant gliomasResponse rateGliomasSuch trialsTraditional treatmentTrialsCodeletion status